Edition:
United Kingdom

Constellation Pharmaceuticals Inc (CNST.OQ)

CNST.OQ on NASDAQ Stock Exchange Global Select Market

7.94USD
16 Aug 2019
Change (% chg)

$0.90 (+12.78%)
Prev Close
$7.04
Open
$7.14
Day's High
$7.95
Day's Low
$7.14
Volume
6,036
Avg. Vol
21,523
52-wk High
$14.04
52-wk Low
$4.01

Latest Key Developments (Source: Significant Developments)

Constellation Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln
Friday, 2 Aug 2019 

Aug 2 (Reuters) - Constellation Pharmaceuticals Inc ::CONSTELLATION PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.  Full Article

Constellation Pharmaceuticals Q1 Loss Per Share $0.75
Wednesday, 8 May 2019 

May 8 (Reuters) - Constellation Pharmaceuticals Inc ::CONSTELLATION PHARMACEUTICALS ANNOUNCES FIRST-QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.75.Q1 EARNINGS PER SHARE ESTIMATE $-0.80 -- REFINITIV IBES DATA.CONSTELLATION PHARMACEUTICALS - CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AS OF MARCH 31, 2019, UP 1.0% COMPARED TO DEC 31, 2018, TO $115.8 MILLION.CONSTELLATION PHARMACEUTICALS - SEES CASH,CASH EQUIVALENTS, MARKETABLE SECURITIES AS OF MARCH 31, 2019, TO FUND OPERATING EXPENSES & CAPEX TO Q3 2020.  Full Article

Constellation Pharmaceuticals Says Plans To Initiate Phase 1 Clinical Trial Of CPI-0209 In Mid-2019
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Constellation Pharmaceuticals Inc ::CONSTELLATION PHARMACEUTICALS PROVIDES UPDATE ON MANIFEST CLINICAL TRIAL OF CPI-0610 IN MYELOFIBROSIS, REVIEWS 2018 ACCOMPLISHMENTS, AND ANNOUNCES 2019 DATA DISCLOSURE PLANS FOR LEAD PROGRAMS.CONSTELLATION PHARMACEUTICALS INC - PLANS TO INITIATE A PHASE 1 CLINICAL TRIAL OF CPI-0209 IN MID-2019.CONSTELLATION PHARMACEUTICALS - AS OF DEC 10, EACH OF FIRST FOUR RUXOLITINIB-RESISTANT SECOND-LINE MF PATIENTS IN MANIFEST REMAINED ON STUDY.CONSTELLATION PHARMACEUTICALS - RESULTS SUGGEST CPI-0610 MAY BE MODIFYING UNDERLYING COURSE OF DISEASE IN THESE RUXOLITINIB-RESISTANT MF PATIENTS.  Full Article